SAN DIEGO, March 1, 2010 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (Nasdaq:HRBR) today announced it will present a poster at the ASCO Genitourinary Cancers Symposium in San Francisco this week, reporting additional results from a Phase I/IIa clinical trial of Apoptone® (HE3235), its anticancer drug candidate being developed for prostate cancer. Apoptone is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to induce cell death (apoptosis) in animal models of prostate and breast cancers.
